A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy

Annals of Allergy, Asthma and Immunology

Volumn 81, Issue 1, 1998, Pages 43-49

  Smith, Lewis J ^a,c   Hanby, Laura A ^b   Lavins, Bernard J ^b   Simonson, Steven G ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ASTRAZENECA   (United Kingdom)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PLACEBO; ZAFIRLUKAST;

ADULT; ARTICLE; ASTHMA; BLOOD SAMPLING; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME RELEASE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

EID: 0031820252     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63108-0     Document Type: Article

References (26)

1. Drazen JM, Austen KF. Leukotrienes and airway responses. Am Rev Respir Dis 1987;136:985-98.
2. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med 1990;323:645-55.
3. Samuelsson B, Dahlen S, Lindren JA, et al. Leukotrienes and lipoxins: structure, biosynthesis, and biological effects. Science 1987;236:1171-6.
4. 4 in humans. Am Rev Respir Dis 1985;131:368-72.
5. 4. JAMA 1983;249:2814-7.
6. 4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol 1988;82: 654-60.
7. 4 and platelet-activating factor on airway reactivity in normal subjects. Am Rev Respir Dis 1990; 141:993-7.
8. Lam S, Chan H, LeRiche JC, et al. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 1988;81:711-7.
9. 4 and histamine in asthmatics. Am Rev Respir Dis 1992;146:96-103.
10. Krell RD, Aharony D, Buckner CK, et al. The preclinical pharmacology of ICI 204,219. Am Rev Respir Dis 1990; 141:978-87.
11. Taylor IK, O'Shaughnessy KM, Fuller RW, et al. Effects of cysteinyl-leukotriene receptor antagonists ICI 204,219 on allergen-induced bronchoconstriction airway hyperreactivity in atopic subjects. Lancet 1991;337:690-4.
12. Finnerty JP, Wood-Baker R, Thomson H, et al. Role of leukotrienes in exercise-induced asthma. Am Rev Respir Dis 1992;145:746-9.
13. Hui KP, Barnes NC. Lung function improvement in asthma with cysteinyl-leukotriene receptor antagonist. Lancet 1991;337:1062-3.
14. 4 receptor antagonist in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-23.
15. Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin Ther 1997;19: 675-90.
16. 4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204, 219. Clin Pharmacol Ther 1993;54:430-6.
17. 4 and methacholine in normal subjects in vivo. Am Rev Respir Dis 1989;139:427-31.
18. American Thoracic Society. Standardization of spirometry - 1994 update. Am J Respir Crit Care Med 1995;152: 1107-36.
19. Bui KH, Kennedy CM, Azumaya CT, et al. Determination of zafirlukast, a selective leukotriene antagonist, in human plasma by normal phase high-performance chromatography with fluorescence detection. J Chromatogr B Biomed Appl 1997;696:131-6.
20. 4) receptor antagonist, on bronchodilation in asthmatic subjects with and without inhaled corticosteroids. Thorax 1997;52:45-8.
21. 4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996;98:528-34.
22. Virchow JC, Hassall SM, Summerton L, et al. Improved asthma control over 6 weeks with ACCOLATE® (zafirlukast) in patients on high-dose inhaled corticosteroids. J Invest Med 1997;45(3):286A.
23. Barnes PJ. Mechanisms of action of glucocorticoids in asthma. Am J Respir Crit Care Med 1996;154:S21-S27.
24. Riddick CA, Ring WL, Baker JR, et al. Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells. Eur J Biochem 1997; 146(1):112-8.
25. Dworski R, Fitzgerald GA, Oates JA, et al. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149:953-9.
26. Sebalt RJ, Sheller JR, Oates JA, et al. Inhibition of eicosanoid biosynthesis by glucocorticosteroids in humans. Proc Natl Acad Sci 1990;87:6974-8.